Financial PerformanceNet loss was $7.5M, or ($0.24) per share, narrower than analyst's estimated loss of $11.0M.
Manufacturing ExpansionProduction workflows are streamlined, efficiently staffed, and ready for expansion in the company's new manufacturing facility in South Salt Lake.
Regulatory StrategyThe company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, following the collection of clinical evaluation data to support the new test's performance.